Sex-specific regulation of microRNAs in Alzheimer Disease

阿尔茨海默病中 microRNA 的性别特异性调控

• 批准号: 10667123
• 负责人: Toni R. Pak
• 金额: $ 66.17万
• 依托单位: LOYOLA UNIVERSITY CHICAGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-15 至 2027-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10667123
• 关键词: Address; Affect; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; BRCA1 gene; Binding; Binding Sites; Biogenesis; Biological; Biological Assay; Brain; Brain region; Cells; Cognition; Complex; Data; Estradiol; Estrogen Receptor beta; Estrogens; Female; Incidence; Kinetics; Length; Link; Longevity; Maps; Mediating; Memory; MicroRNAs; Microprocessor; Molecular; Organ; Pathway interactions; Pattern; Postmenopause; Process; Proteins; Proteomics; RNASE3L gene; Regulation; Research; Sex Bias; Sex Differences; Signal Pathway; Signal Transduction; Specificity; Testing; Therapeutic; Time; Tissues; Trans-Activators; Transcript; Untranslated RNA; Woman; age effect; age related; aging brain; body system; deprivation; experimental study; hnRNP-H; men; normal aging; novel; posttranscriptional; sex; trafficking; treatment strategy

PROJECT SUMMARY Alzheimer’s Disease is more prevalent in women than men, yet a biological basis for this sex difference is not understood. The primary objective of this proposal is to understand how 17β-estradiol (E2) regulates microRNA (miR) biogenesis and stability across the lifespan and in Alzheimer’s Disease (AD). We hypothesize that dysregulation of E2-mediated miR expression in the aged brain leads to greater Alzheimer Disease risk in women. The studies proposed are focused on understanding how estrogens regulate these miRs to get a better understanding of their dysregulation in AD - specifically in women. This will address a major gap in our understanding because how E2 influences the components of the miR biogenesis pathway to regulate mature miR expression levels in a cell- and/or age-specific manner is unknown, despite several studies demonstrating temporal and cell-specific effects of E2 on miR expression in a variety of organ systems. Our prior studies demonstrated that E2 treatment altered the expression levels of a subset of miRs in the female brain, and the ability to regulate these miRs depended on age, brain region, and length of E2 deprivation (i.e., time post- menopause). Collectively the experiments in Aim 1 will test the hypothesis that E2 differentially mediates mature miR stability depending on age and in Alzheimer’s Disease. We will use miR degradation assays to determine whether age and/or E2 affect the rate of miR degradation and, using a proteomics approach, identify the cis- and trans-acting factors that regulate miR stability. Aim 2 will addresses mechanistically how a select subset of miRs could be specifically regulated by E2 post-transcription. We will test the hypothesis that hnRNP H binding to ERβ reduces its association with pri-miR transcripts, ERβ interacts with BRCA1 to differentially facilitate DROSHA complex assembly, and that these interactions are dependent on age and E2 treatment. Aim 3 will determine the effects of age and E2 on miR subcellular localization and assess disruption of E2- mediated miR subcellular localization in Alzheimer’s Disease. This aim will test the hypothesis that E2 facilitates subcellular trafficking of miRs, thereby impacting miR function. Moreover, we will test the hypothesis that miR subcellular localization changes across the lifespan and that normal age-related subcellular localization is disrupted in Alzheimer’s Disease. Impact: Understanding the basic molecular signaling pathways of E2 in the aging brain will help drive therapeutic advances and inform treatment strategies for women with Alzheimer’s Disease.

项目总结